A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
To determine preliminary efficacy measured by patient reported fatigue using the Brief Fatigue Inventory (BFI) at 8 eeks of two doses (150mg and 250mg) of armodafmil in treating moderate fatigue compared to placebo in patients with high grade glioma.
Study Number: 

NCG 286716

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.